Loading...
•
Dec 31, 2019
Eton Q4 2019 Earnings Report
Eton reported Q4 2019 financial results, marking its transition to a commercial revenue company with the launch of Biorphen.
Key Takeaways
Eton Pharmaceuticals reported revenue of $0.5 million for the fourth quarter of 2019, driven by initial Biorphen stocking orders. The company's net loss for the quarter was $2.7 million. As of December 31, 2019, Eton had cash and cash equivalents of $12.1 million.
Launched Biorphen, the first FDA-approved ready-to-use formulation of phenylephrine injection, in December.
Initial customer demand for Biorphen led to purchases by over 100 institutions.
Entered into a co-promotion arrangement with Xellia Pharmaceuticals for Biorphen.
Submitted the ANDA for DS-300 in December.
Forward Guidance
Eton is focused on earning additional product approvals in 2020 and driving customer adoption of Biorphen.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...